AbbVie expects performance in 2H18 to continue to be ‘robust’

Says delivered “strong” topline results in the quarter driven by growth from several assets across the portfolio, including Humira, Imbruvica and. Mavyret. Expects performance in the 2H18 to continue to be “robust”. Says expects Imbruvica momentum to continue. Says Mavyret has achieved market-leading position in the U.S. Says continues to make “excellent progress” with late-stage R&D products. Says Orilissa represents a significant long-term opportunity. Says remains on track to submit regulatory application for upadacitinib later this year. Says submitted BLA and MAA for risankizumab. Expects further diversification going forward. Expects to be “extremely well-positioned” by 2020 with diversified assets. Says confident in ability to continue to drive strong growth. Comments taken from Q2 earnings conference call.
https://bit.ly/2K1ATb9